1. >
  2. Investors
  3. >
  4. Regulated Information
  5. >
  6. Press Releases – Reg...

PRESS RELEASES

Found 286 Results
Page 3 of 29

Onxeo Announces its Financial Agenda for 2021


Paris (France), January 7, 2021 – 6 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

01/07/2021



Onxeo Announces the Transfer of the Listing of its Shares to Euronext Growth Paris on December 15, 2020


Paris (France), December 10, 2020 – 6 pm CET – Onxeo S.A. (ISIN: FR0010095596), (“Onxeo” or “the Company”), a clinical-stage […]

12/10/2020




Onxeo Has Applied for Admission to Trading on Nasdaq First North Growth Market Denmark and Delisting from Nasdaq Main Market Copenhagen


Paris (France), November 27, 2020 – 6 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

11/27/2020


Onxeo Announces Completion of Patient Enrollment in DRIIV-1b Study and Positive Interim Results


The last patient was treated with AsiDNA™ in combination with carboplatin and paclitaxel in this Phase 1b study in patients […]

Tags:

11/09/2020


Onxeo Receives Notice of Intent to Grant a New Patent Enhancing the Protection in Europe of AsiDNA™ Combined with PARP Inhibitors


This new patent protects the method of use of AsiDNA™ in combination with PARP inhibitors in the treatment of HR-proficient […]

Tags:

10/22/2020


Onxeo Announces Enrollment of First Patient in Phase Ib/II Study Revocan


Revocan is designed to evaluate the abrogation by AsiDNA™ of tumor resistance to a PARP inhibitor in relapsed ovarian cancer […]

Tags:

10/21/2020


Publication of the 2020 Half-Yearly Financial Report


Paris (France), September 29, 2020 – 6.00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” […]

09/29/2020


Page 3 of 29